-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, NqW5/xD4W97XYs3H1/KQH5RvjrrbTJtxXNNnI+RZPVB3SdwiDwYO254U7U3BJNnM KzFolJM0IUajdwV6TEDqtQ== 0001193125-10-132667.txt : 20101014 0001193125-10-132667.hdr.sgml : 20101014 20100604100934 ACCESSION NUMBER: 0001193125-10-132667 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20100604 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PHARMACEUTICAL PRODUCT DEVELOPMENT INC CENTRAL INDEX KEY: 0001003124 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 561640186 STATE OF INCORPORATION: NC FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 929 NORTH FRONT STREET CITY: WILMINGTON STATE: NC ZIP: 28401 BUSINESS PHONE: 9102510081 MAIL ADDRESS: STREET 1: 929 NORTH FRONT STREET CITY: WILMINGTON STATE: NC ZIP: 28401 CORRESP 1 filename1.htm Correspondence

Wyrick Robbins Yates & Ponton LLP

4101 Lake Boone Trail, Suite 300

Raleigh, North Carolina 27607

Donald R. Reynolds

dreynolds@wyrick.com

June 3, 2010

VIA EDGAR

Division of Corporation Finance

U.S. Securities and Exchange Commission

100 F Street N.E.

Washington, DC 20549

Attention: Rose Zukin

 

  Re: Pharmaceutical Product Development, Inc.

Form 10-K for the year ended December 31, 2009

Filed February 26, 2010

Schedule 14A filed April 1, 2010

File No. 000-27570

Ladies and Gentlemen:

We write this letter on behalf of our client Pharmaceutical Product Development, Inc. (the “Company”) in response to the comments of the Staff of the Securities and Exchange Commission with respect to the above-captioned filing, as set forth in the Staff’s letter dated May 26, 2010. In a telephone conversation on June 2, 2010, between the undersigned and Rose Zukin of the Staff, the undersigned conveyed the Company’s request to extend the deadline to respond to the Staff’s comments to June 23, 2010. This letter will serve to memorialize that request.

U.S. Securities and Exchange Commission

June 3, 2010

Page 2 of 2

 

If the Staff has any further comments, please direct them to the undersigned.

 

Sincerely,
/s/ Donald R. Reynolds
Donald R. Reynolds

 

cc: Daniel Darazsdi

Judd Hartman

-----END PRIVACY-ENHANCED MESSAGE-----